Corvus Pharmaceuticals (CRVS) Rating Increased to Sell at ValuEngine

Corvus Pharmaceuticals (NASDAQ:CRVS) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Wednesday.

A number of other equities research analysts have also recently issued reports on CRVS. Zacks Investment Research cut Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Cowen restated a “buy” rating on shares of Corvus Pharmaceuticals in a research note on Friday, March 2nd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $18.67.

How to Become a New Pot Stock Millionaire

Shares of Corvus Pharmaceuticals stock traded down $0.53 on Wednesday, reaching $10.38. 25,847 shares of the company were exchanged, compared to its average volume of 120,548. Corvus Pharmaceuticals has a one year low of $7.42 and a one year high of $17.64.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, March 1st. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.18. equities analysts expect that Corvus Pharmaceuticals will post -3.15 earnings per share for the current fiscal year.

In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, March 12th. The shares were acquired at an average price of $8.50 per share, for a total transaction of $850,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Adams Street Partners Llc purchased 588,235 shares of the company’s stock in a transaction that occurred on Monday, March 12th. The stock was acquired at an average price of $8.50 per share, for a total transaction of $4,999,997.50. Following the purchase, the insider now owns 4,420,516 shares in the company, valued at approximately $37,574,386. The disclosure for this purchase can be found here. 46.40% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System grew its holdings in Corvus Pharmaceuticals by 121.2% in the 2nd quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock valued at $181,000 after buying an additional 8,200 shares in the last quarter. State Street Corp grew its holdings in Corvus Pharmaceuticals by 18.6% in the 2nd quarter. State Street Corp now owns 62,475 shares of the company’s stock valued at $756,000 after buying an additional 9,779 shares in the last quarter. Deutsche Bank AG grew its holdings in Corvus Pharmaceuticals by 118.1% in the 4th quarter. Deutsche Bank AG now owns 19,058 shares of the company’s stock valued at $196,000 after buying an additional 10,320 shares in the last quarter. SG Americas Securities LLC acquired a new position in Corvus Pharmaceuticals in the 4th quarter valued at $150,000. Finally, Goldman Sachs Group Inc. acquired a new position in Corvus Pharmaceuticals in the 4th quarter valued at $253,000. 82.71% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Corvus Pharmaceuticals (CRVS) Rating Increased to Sell at ValuEngine” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3335039/corvus-pharmaceuticals-crvs-rating-increased-to-sell-at-valuengine.html.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

WNS Global Services  Expected to Post Earnings of $0.57 Per Share
WNS Global Services Expected to Post Earnings of $0.57 Per Share
-$0.04 EPS Expected for Coeur Mining  This Quarter
-$0.04 EPS Expected for Coeur Mining This Quarter
Head-To-Head Analysis: Omni Lite Industries Canada  vs. Park-Ohio
Head-To-Head Analysis: Omni Lite Industries Canada vs. Park-Ohio
Reviewing Caladrius Biosciences  & Tivity Health
Reviewing Caladrius Biosciences & Tivity Health
Comparing Pacific Ethanol  and Its Peers
Comparing Pacific Ethanol and Its Peers
Somewhat Positive Media Coverage Somewhat Unlikely to Affect Capital Product Partners  Share Price
Somewhat Positive Media Coverage Somewhat Unlikely to Affect Capital Product Partners Share Price


© 2006-2018 Ticker Report. Google+.